Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
J Infect. 2020 Sep; 81(3): e12–e15.
Published online 2020 Jul 8. doi: 10.1016/j.jinf.2020.07.010
PMCID: PMC7342079
PMID: 32652163

Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae

Lei Zha,a,b,1 Jian Shen,c,1 Boris Tefsen,a Yujun Wang,d, Weihua Lu,e, and Qiancheng Xue,⁎,1

Associated Data

Data Availability Statement

Dear Editor,

A recent review published by the Journal of Infection raised concerns towards co-infection with Mycoplasma pneumoniae (MP) in coronavirus disease 2019 (COVID-19) patients.1 It is difficult to distinguish between COVID-19 with or without MP co-infection because of the overlapping manifestations and image features. Similar clinical characteristics, complications, and outcomes were reported for patients infected with either MP alone or with viral co-infection.2 Until now, the morbidity of co-infection with MP in COVID-19 patients and whether co-infection with MP has worse clinical outcomes have not been reported yet and thus remain uncertain.

To answer these questions, we conducted a retrospective observational study in The Central Hospital of Wuhan from January 15, 2020, to March 15, 2020. For diagnosing COVID-19, a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was performed with sputum or throat swab samples. To establish MP infection, IgM chemiluminescence immunoassay was used (MP IgM positive and antibody titer ≥ 1:1603) or positive results for MP RT-PCR tests of throat swabs.3 Comorbidity, clinical manifestation, laboratory findings, and outcomes were collected from all patients. The study was approved by the ethics committee of The Central Hospital of Wuhan (Ethics 2020-34).

Among a total of 874 patients with laboratory-confirmed COVID-19, the overall rate of M. pneumoniae co-infection was 2.5% (22 of the 874 patients). In this study, 88 patients with COVID-19 mono-infection were matched as the control group using the propensity score. Patients co-infected with influenza or other bacteria besides MP were excluded from both groups. The characteristics, treatment, and clinical outcomes are summarized in Tables 1 and and22 .

Table 1

Baseline characteristics of coronavirus disease 2019 (COVID-19) and M. pneumoniae co-infection patients.

CharacteristicsCOVID-19 mono-infection patients (n = 88)COVID-19 patients co-infection with M. pneumoniae (n = 22)p
Baseline
Age (years)57.00 (46.50–65.00)56.50 (52.50–66.50)0.726
Male45 (51.1)11 (50.0)1.000
Time from illness onset to hospital admission (days)10.50 (7.00–20.00)14.50 (5.50–20.00)0.666
Comorbidities
Diabetes20 (22.7)5 (22.7)1.000
Hyperlipemia3 (3.4)1 (4.5)1.000
Hypertension16 (18.2)4 (18.2)1.000
Chronic heart failure2 (2.3)1 (4.5)1.000
Liver cirrhosis2 (2.3)2 (9.1)0.373
Anemia6 (6.8)2 (9.1)1.000
Chronic kidney diseases1 (1.1)1 (4.5)0.858
Rheumatoid arthritis0 (0.0)2 (9.1)0.05
Cerebrovascular disease1 (1.1)1 (4.5)0.858
Myasthenia Gravis1 (1.1)1 (4.5)0.858
Deep venous thrombosis0 (0.0)1 (4.5)0.451
COPD6 (6.8)1 (4.5)1.000
Symptoms
Fever55 (62.5)10 (45.5)0.226
Cough27 (30.7)4 (18.2)0.368
Dyspnea7 (8.0)2 (9.1)1.000
Fatigue6 (6.8)4 (18.2)0.214
Diarrhea2 (2.3)2 (9.1)0.373
Chestpain1 (1.1)0 (0.0)1.000
Dizzy0 (0.0)1 (4.5)0.451
other11 (12.5)4 (18.2)0.728
Signs
Respiratory rate36.70 (36.50–37.02)36.50 (36.30–36.98)0.096
Heart rate86.00 (79.75–97.25)94.00 (79.25–98.50)0.437
Systolic pressure (mmHg)20.00 (18.00–20.00)19.50 (18.00–20.00)0.273
Diastolic pressure (mmHg)130.00 (120.00–139.25)127.00 (116.00–143.25)0.672
Peripheral oxygen saturation (%)80.00 (73.50–87.00)82.50 (72.75–88.50)0.624
Laboratory tests
White blood cell count (× 109/L)5.63 (4.90–7.08)5.81 (5.13–6.84)0.627
Neutrophil count (× 109/L)3.55 (2.91–5.19)3.35 (2.64–5.43)0.725
Lymphocyte count (× 109/L)1.35 (0.91–1.73)1.63 (1.20–2.04)0.167
Monocyte count (× 109/L)0.39 (0.31–0.51)0.38 (0.33–0.56)0.257
Hemoglobin (g/L)131.00 (119.00–142.00)123.00 (118.50–130.50)0.087
Platelet count (× 109/L)204.00 (165.75–258.25)187.50 (144.00–250.25)0.269
Albumin (g/L)39.90 (36.90–43.85)41.65 (36.12–43.05)0.858
Alanine aminotransferase (ALT) (U/L)22.70 (15.10–33.15)23.15 (13.98–33.23)0.949
Aspartate aminotransferase (AST) (U/L)19.60 (15.00–26.25)19.30 (14.53–23.70)0.834
Direct Bilirubin (μmol/L)3.28 ± 2.1519.19 ± 72.260.039
Indirect Bilirubin (μmol/L)8.03 ± 4.0714.67 ± 28.720.037
Creatine (μmol/L)68.15 (55.82–88.95)56.70 (50.48–72.72)0.057
Urea (mmol/L)4.50 (3.83–5.60)4.21 (3.34–4.54)0.151
Creatine kinase (U/L)70.50 (49.75–115.75)66.00 (48.75–78.75)0.279
Creatine kinase -MB (U/L)6.00 (5.00–9.00)7.15 (5.00–11.40)0.324
Troponin (ng/mL)0.00 (0.00–0.01)0.01 (0.00–0.03)0.12
Brain Natriuretic Peptid (pg/mL)32.50 (14.88–85.75)58.50 (20.75–126.85)0.245
Lactate dehydrogenase (U/L)156.00 (138.00–194.75)177.00 (141.00–208.25)0.52
Blood glucose (mmol/L)5.29 (4.70–6.99)5.55 (5.12–7.25)0.358
Sodium (mmol/L)140.00 (137.57–142.00)139.50 (138.00–140.90)0.386
Potassium (mmol/L)4.21 (3.97–4.50)4.16 (4.01–4.39)0.572
Calcium (mmol/L)2.29 (2.19–2.45)2.38 (2.28–2.45)0.188
Chloride (mmol/L)103.30 (102.02–106.40)104.20 (101.17–106.48)0.934
Phosphorus (mmol/L)1.09 (0.93–1.22)1.11 (0.98–1.22)0.731
Prothrombin Time (s)13.34 ± 5.4011.60 ± 0.840.004
International Normalized Ratio1.16 ± 0.501.00 ± 0.080.005
Prothrombin Activity (%)89.78 ± 30.65104.90 ± 20.140.006
Activated Partial Thromboplastin Time (s)31.07 ± 8.8828.53 ± 5.150.082
Thrombin Time (s)16.95 ± 1.7916.88 ± 1.540.86
Fibrinogen (g/L)2.52 (2.17–3.05)2.37 (2.09–2.60)0.121
D-dimer (ug/mL)0.45 (0.25–1.02)0.72 (0.44–1.61)0.062
Interleukin-6 (pg/mL)4.49 (2.26–12.34)2.90 (2.08–5.89)0.138
Procalcitonin (ng/ml)0.05 (0.04–0.08)0.05 (0.03–0.07)0.382
C Reactive Protein (mg/dl)0.36 (0.12–2.63)0.24 (0.10–2.08)0.452

Table 2

Treatments and clinical outcomes in COVID-19 and M. pneumoniae co-infection patients.

Treatments and outcomesCOVID-19 mono-infection patients (n = 88)COVID-19 patients co-infection with M. pneumoniae (n = 22)p
Treatments
Antivirals
Umifenovir74 (84.1)16 (72.7)0.354
Ribavirin58 (65.9)18 (81.8)0.235
Interferon alpha inhalation1 (1.1)0 (0.0)1.000
Lopinaviritonavir2 (2.3)1 (4.5)1.000
Oseltamivir11 (12.5)4 (18.2)0.728
Antibiotics24 (85.7%)47 (87%)
Fluoroquinolones31 (35.2)18 (81.8)<0.001
Cephalosporins23 (26.1)11 (50.0)0.056
Amoxicillin and Clavulanate Potassium0 (0.0)3 (13.6)0.005
Corticosteroids25 (28.4)14 (63.6)0.005
Outcomes
Discharge86 (97.7)21 (95.5)1.000
Death2 (2.3)1 (4.5)..
Length of cough16.25 (12.25–22.50)20.00 (12.00–25.75)0.043
Length of hospital stay (days)16.00 (10.00–22.25)14.00 (7.25–18.25)0.145
Severity of disease
Mild84 (95.5)21 (95.5)1.000
Moderate4 (4.5)1 (4.5)..

The median age of COVID-19 mono-infection patients was 57.00 (46.50–65.00) years, which was similar to that of MP co-infection patients who were 56.50 (52.50–66.50) years. There were no significant differences in the major complaints on admission between the two groups. The major complaints on admission were fever (59.1%), cough (28.2%), dyspnoea (8.2%), fatigue (9.1%), and diarrhoea (3.6%) in all the patients. However, one patient (1.1%) in the mono-infection group reported chest pain and one patient in the co-infection group mentioned dizziness (4.5%). Likewise, most of the comorbidities were similar in both groups, except for rheumatoid arthritis (RA) that was reported in the MP co-infection group (9.1% vs 0.0%, p = 0.05). Wakabayashi et al.4 reported that MP was one of the most frequent causative microbial agents of pneumonia in RA patients and the mortality was statistically higher in those patients than in non-RA patients suffering from pneumonia.

Patients coinfected with MP were more likely to have higher bilirubin levels compared with patients infected with COVID-19 alone (14.67 ± 28.72 vs 8.03 ± 4.07, p = 0.037). Pooled analysis of six studies show that bilirubin concentration was significantly higher in patients with severe COVID-19 (SMD: 0.48 μmol/L; 95% CI, 0.11-0.85 μmol/L, p = 0.012).5 In sepsis, a higher serum bilirubin level at ICU admission is associated with subsequent ARDS development and mortality.6 However, there was no similar trend of ARDS development and mortality observed in this study. Previous studies reported that COVID-19 with liver injury is associated with poorer clinical outcomes. Alanine aminotransferase (AST) abnormality was associated with the highest mortality risk compared to other indicators. However, in our study, AST was almost at a normal level, hence there was no evidence to support co-infection with MP could lead to liver injury and increase mortality in COVID-19 patients.

Both M. pneumoniae pneumonia (MMP) and COVID-19 have been reported to induce hypercoagulability[7], Moreover, in children with MPP, complications as acute cerebral infarction and pulmonary embolism have been reported.8 In patients with COVID-19, Zhang L. et al7 reported that D-dimer on admission more than 2.0 µg/mL could effectively predict in-hospital mortality. In our study, Prothrombin Time (11.60 ± 0.84 s vs 13.34 ± 5.4 s, p = 0.004) was shorter and Prothrombin Activity (104.90 ± 20.14 s vs 89.78 ± 30.65 s, p = 0.006) was higher in the co-infection group. Therefore, COVID-19 co-infection with MP has an even higher risk of blood coagulation, and thrombosis than the mono-infected patients and routine anticoagulation prophylactics is strongly recommended.

Quinolone antibiotics were more frequently administered to the patients with MP co-infection (81.8% vs. 35.2%, p < 0.001), and corticosteroids were more frequently administered to patients with MP co-infection (63.6% vs. 28.4%, p = 0.005). However, different antibiotics and corticosteroids strategy showed no associations with a better outcome.

Previous studies reported that children with MMP co-infected with human bocavirus, human rhinovirus, or respiratory syncytial virus had a longer fever process, higher leukocyte count, higher C-reactive protein, higher percentage of pneumothorax and diffuse large area of inflammation in chest X-ray compared with mono-infection.9 However, in our study the severity of disease was comparable in the two groups, and most patients were categorized as having moderate pneumonia (95.5% vs. 95.5%) in both groups. The overall clinical outcome was good in this study; only one fatal case in co-infection group and two fatal case in mono-infection group were reported (4.5% vs. 2.3%, p = 1.00). The length of cough was longer in the MP co-infection group [20.00 (12.00–25.75) vs 16.25 (12.25–22.50), p = 0.043], while the length of hospital stay was slightly longer [16.00 (10.00–22.25) vs 14.00 (7.25–18.25), p = 0.145], but without statistical significance. In previous study,2 a similar association of length of hospital stay and length of cough was found in MMP children co-infected with viruses like adenovirus, influenza A, respiratory syncytial virus and bacteria like Streptococcus pneumoniae

There are some limitations in our study. First, using IgM to diagnose MP co-infection may lead to false negative, the sensitivity of IgM serology was 81.82%.10 Second, our study may have the selective bias because children were not included in our study.

In conclusion, our study is the first to describe the clinical features and outcomes of COVID-19 patients co-infected with MP. There were no significant associations between MP co-infection and major complaints on admission, but an approximate of 4 days increasement in the length of cough was reported. Importantly, the already elevated risk of thrombosis in COVID-19 patients is significantly increased by the co-infection with MP.

Authors’ contributions

Lu, Wang and Xu, the corresponding author, were responsible for the conceptualization of the study, the revision and approval of this manuscript. Lei and Shen participated in the design and drafted the manuscript, collected data and were responsible for its accuracy. Tefsen helped to revise the manuscript. All authors contributed to the data analysis and interpretation. All authors read and approved the final manuscript.

Declaration of Competing Interest

None.

Acknowledgments

Not applicable.

Funding

This work was supported, in part, by the Anhui Provincial Special Project of Central Government Guiding Local Science and Technology Development of China (201907d07050001) and the special fund for coronavirus disease 2019 of Wuhu (no. 2020dx2-1).

Availability of data and materials

Data are available on request.

Ethics approval

The study was approved by the ethics committee of the Central Hospital of Wuhan (Ethics 2020-34).

Consent for publication

All authors have approved the manuscript and its publication.

References

1. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 [PMC free article] [PubMed] [Google Scholar]
2. Chiu C.Y., Chen C.J., Wong K.S., Tsai M.H., Chiu C.H., Huang Y.C. Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. J Microbiol Immunol Infect. 2015;48(1):51–56. [PubMed] [Google Scholar]
3. Wang L., Feng Z., Zhao M., Yang S., Yan X., Guo W., Shi Z., Li G. A comparison study between GeXP-based multiplex-PCR and serology assay for Mycoplasma pneumoniae detection in children with community acquired pneumonia. BMC Infect Dis. 2017;17(1):518. [PMC free article] [PubMed] [Google Scholar]
4. Wakabayashi A., Ishiguro T., Takaku Y., Miyahara Y., Kagiyama N., Takayanagi N. Clinical characteristics and prognostic factors of pneumonia in patients with and without rheumatoid arthritis. PLOS ONE. 2018;13(8) [PMC free article] [PubMed] [Google Scholar]
5. Paliogiannis P., Zinellu A. Bilirubin levels in patients with mild and severe Covid-19: a pooled analysis. Liver Int. 2020;40(7):1787–1788. [PMC free article] [PubMed] [Google Scholar]
6. Zhai R., Sheu C.C., Su L., Gong M.N., Tejera P., Chen F., Wang Z., Convery M.P., Thompson B.T., Christiani D.C. Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis. Thorax. 2009;64(9):784–790. [PMC free article] [PubMed] [Google Scholar]
7. Zhang L., Yan X., Fan Q., Liu H., Liu X., Liu Z., Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329. [PMC free article] [PubMed] [Google Scholar]
8. Garcia A.V., Fingeret A.L., Thirumoorthi A.S., Kadenhe-Chiweshe A., Kandel J.J. Severe Mycoplasma pneumoniae infection requiring extracorporeal membrane oxygenation with concomitant ischemic stroke in a child. Pediatr Pulmonol. 2013;48(1):98–101. [PubMed] [Google Scholar]
9. Zhang X., Chen Z., Gu W., Ji W., Wang Y., Hao C., He Y., Huang L., Wang M., Shao X. Viral and bacterial co-infection in hospitalised children with refractory Mycoplasma pneumoniae pneumonia. Epidemiol Infect. 2018;146(11):1384–1388. [PMC free article] [PubMed] [Google Scholar]
10. Medjo B., Atanaskovic-Markovic M., Radic S., Nikolic D., Lukac M., Djukic S. Mycoplasma pneumoniae as a causative agent of community-acquired pneumonia in children: clinical features and laboratory diagnosis. Ital J Pediatr. 2014;40:104. [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Infection are provided here courtesy of Elsevier